Geetha Shankar

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck, Tony Mok, Makoto Nishio et al. · The Lancet Respiratory Medicine · 2019 · 939 citations

Medicine, Oncology, Pharmacology +17

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Mark A. Socinski, Makoto Nishio, Robert M. Jotte et al. · Journal of Thoracic Oncology · 2021 · 523 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Solange Peters, Scott Gettinger, Melissa L. Johnson et al. · Journal of Clinical Oncology · 2017 · 419 citations · Full text

Medicine, Oncology, Pharmacology +17

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski et al. · Journal of Thoracic Oncology · 2021 · 303 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Marcin Kowanetz, Wei Zou, Scott Gettinger et al. · Proceedings of the National Academy of Sciences · 2018 · 239 citations · Full text

Medicine, Immunology, Pharmacology +17